doi: 10.1097/00002030-200307040-00021.
Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine
Affiliations
- PMID: 12824799
- DOI: 10.1097/00002030-200307040-00021
Item in Clipboard
Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine
AIDS.
.
Abstract
Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.
Similar articles
-
NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.Antiviral Res. 2007 Nov;76(2):99-103. doi: 10.1016/j.antiviral.2007.06.002. Epub 2007 Jul 2. Antiviral Res. 2007. PMID: 17640745
-
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.J Med Virol. 2001 Nov;65(3):445-8. J Med Virol. 2001. PMID: 11596076
-
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906. Antivir Ther. 2011. PMID: 22024527 Clinical Trial.
-
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.Antivir Ther. 2001;6 Suppl 3:25-44. Antivir Ther. 2001. PMID: 11678471 Review.
-
HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S2-7. doi: 10.1097/00126334-200309011-00002. J Acquir Immune Defic Syndr. 2003. PMID: 14562852 Review.
Cited by
-
A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.J Virol. 2010 May;84(10):5238-49. doi: 10.1128/JVI.01545-09. Epub 2010 Mar 10. J Virol. 2010. PMID: 20219933 Free PMC article.
-
Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Virol J. 2015 Nov 14;12:187. doi: 10.1186/s12985-015-0417-y. Virol J. 2015. PMID: 26578099 Free PMC article.
-
Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.Antimicrob Agents Chemother. 2004 Dec;48(12):4611-7. doi: 10.1128/AAC.48.12.4611-4617.2004. Antimicrob Agents Chemother. 2004. PMID: 15561833 Free PMC article.
-
High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.Antimicrob Agents Chemother. 2005 Nov;49(11):4546-54. doi: 10.1128/AAC.49.11.4546-4554.2005. Antimicrob Agents Chemother. 2005. PMID: 16251294 Free PMC article.
-
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.J Virol. 2008 Apr;82(7):3261-70. doi: 10.1128/JVI.01154-07. Epub 2008 Jan 23. J Virol. 2008. PMID: 18216099 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
